Ten years ago, a consensus report on the optimization of tacrolimus was published in this
journal. In 2017, the Immunosuppressive Drugs Scientific Committee of the International …

ATP-binding cassette transporter B1 (ABCB1; P-glycoprotein; multidrug resistance protein 1)
is an adenosine triphosphate (ATP)-dependent efflux transporter located in the plasma …

The calcineurin inhibitors ciclosporin (cyclosporine) and tacrolimus are immunosuppressant
drugs used for the prevention of organ rejection following transplantation. Both agents are …

In 2007, a consortium of European experts on tacrolimus (TAC) met to discuss the most
recent advances in the drug/dose optimization of TAC taking into account specific clinical …

The calcineurin inhibitor tacrolimus is the backbone of immunosuppressive drug therapy
after solid organ transplantation. Tacrolimus is effective in preventing acute rejection but has …

Retrospective studies have demonstrated that patients who are expressors of cytochrome
P4503A5 (CYP3A5) require a higher tacrolimus dose to achieve a therapeutic trough …

Many studies have attempted to explain the interindividual variability observed in drug
metabolism by assessing the impact of SNPs in genes implicated in drug absorption …

BACKGROUND Tacrolimus (Tac) is a potent immunosuppressant with considerable toxicity.
Tac pharmacokinetics varies between individuals and thus complicates its use in preventing …

Aims: CYP3A4 is involved in the oxidative metabolism of many drugs and xenobiotics
including the immunosuppressants tacrolimus (Tac) and cyclosporine (CsA). The objective …

The impact of CYP3A and MDR1 gene single‐nucleotide polymorphisms on long‐term
tacrolimus disposition and drug‐related toxicity has not been assessed. A study was …